This more recent work by Mitalipov's group dealt with single cell embryo and still ended up with mosaicism, which I was a bit surprised at first. But when you think about it, this single-cell embryo's genome is actively being replicated, so not 100% of the alleles will be edited.
A way around it, would be to reactivate Cas9 after every cell division event, or maybe applying Cas9 gene-drive to embryo development. Also, I have yet to see a CRISPR paper with ensemble sequencing showing no off-targets. Even all the enhanced specificity Cas9 variants had a small percentage of off-targets.
Many of the worst disorders are lack of function mutations where mosaicism would indeed fix it.
I would be more worried about unwanted edits than missing ones.
The same mosaicism phenomenon which cause tabby cat's coat (especially callico) can be seen in human and would cause that individual to sweat by plaques, instead of the entire body. So you could imagine a scenario where someone would like to select a specific eye, or hair, or skin pigmentation, and end up with inequal pigmentations or a patchwork. That actually sounds cool...
In the case of an autoimmune disorder, like type-I diabetes or a blood disorders like beta-thalassemia, you would absolutely need to hit the proper germline which is responsible for creating your diseased cells. So that's a hit or miss, there is no inbetween. If you do have a hit, then while this germline is dividing and differentiating, it would need to reach a threshold at which the disease becomes asymptomatic. I don't what that number is for any of two diseases I just mentioned, but I would think it is higher than 50% of your cells that need to be corrected, so you would need to successfully hit more than one allele in your succesfully hit germline population that will become blood making cells.
It's a lot of moving parts, which needs to align correctly. That being said, I am optimistic that we will eventually get there. I have some doubt about the scientific pertinence of that "breaking news", i.e. I just don't believe they have accomplished anything that wasn't obvious, but being an optimist, I am sure that not all the ink will be a waste.
Nice question.
It comes from the hippocratic oath. "I will apply dietetic measures for the benefit of the sick according to my ability and judgment; I will keep them from harm and injustice."
Not really:
"In a 2000 survey of US medical schools, all of the then extant medical schools administered some type of profession oath. Among schools of modern medicine, sixty-two of 122 used the Hippocratic Oath, or a modified version of it."
Like I said in my previous post, some schools use a modern rendition. The modern versions don't forbid surgery, the use of poison, abortive measures, or compensation for medical training--necessary features of modern healthcare.
I challenge you to find me one med school that uses the original oath.
Medical ethics these days follows a principle-based system. The most common framework employs four basic moral principles: respect for autonomy, beneficence, non-maleficence, and justice. The current system of ethics is far more robust than any of the pledges taken. The pledges are more about personal significance and have no legal or procedural weight.
Obviously it's net harm, not no harm at all.
Medical ethics is its own field precisely because overeager and overconfident solutions are fraught with problems.
But what about if somebody donates a kidney...? Hm
> It is often said that the phrase "First do no harm" (Latin: Primum non nocere) is a part of the Hippocratic oath. The phrase as such does not appear in the oath...
What? I encourage you to read about prescription drug side effects. If a drug were safe, it would be over the counter rather than prescription. Prescription drugs are exactly the kind of harm/benefit bundle GP is describing.
Assessing treatments on thereputic merit - does a treatment create significantly more benefit than it does harm (As chemotherapy is a standard bearing example), is, based on the evidence I've observed, the preferable approach.
I do see one argument, hinging on the difference between an embryo and an adult aged many years. If your argument is that better techniques may exist at the embryonic stage, then I submit to the medical community to ascertain the appropriate course. However, I don't think offsite mutations pose a significant enough risk that one can say that, on aggregate, gene editing won't "do some good".